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ABSTRACT Structural and functional analyses of myeloma
immunoglobulins from inbred BALB/c mice and humans have
provided important insights into the structure of the antibody
molecule and the expression and evolution of antibody genes.
One important question concerning these analyses is whether
the myeloma process selects, in a nonrandom manner, the
lymphocytes to be transformed. The availability of myeloma
tumors in a second inbred strain of mouse, NZB, permits us to
approach this question. In this respect, the NHrterminal amino
acid sequences of 27- ,light chains as well as data relating to the
antigen-binding properties and immunoglobulin class distri-
bution of NZB myeloma proteins are presented and compared
with similar data from the BALB/c mouse. These studies
suggest that the myeloma proteins from the BALB/c and NZB
mice constitute two populations of immunoglobulins with dis-
tinct functional and structural properties. The implications of
this observation are discussed.
Myeloma tumors may be artificially induced by injecting
mineral oil into the peritoneal cavity of inbred BALB/c mice
(1). Chemical analysis of the homogeneous immunoglobulins
derived from these myeloma tumors has provided important
insights into the structure, genetics, and evolution of antibody
molecules and genes (2, 3). Moreoever, the observations that
immunoglobulin variable regions can be divided into related
sets or subgroups of sequences and that there are regions of
extreme variability, termed "hypervariable regions," have
placed important constraints on the modern theories of antibody
diversity (4). Indeed, our estimates as to the complexities of the
various immunoglobulin gene families have been derived from
the nature and extent of the heterogeneity seen in the corre-
sponding myeloma proteins. Thus, it is important to determine
whether the highly artificial process of myeloma induction
provides a random sampling of lymphocyte diversity in the
mouse. For example, if only 10% of the lymphocyte population
were capable of being transformed by the myeloma process,
then diversity estimates would be too low by a factor of 10. The
availability of a second inbred mouse strain, NZB, in which
myeloma tumors can be induced gave us an opportunity to
examine this question.
It should be noted that three observations suggest that
BALB/c myeloma proteins may represent only a selected subset
of the antibody variable (V) regions. First, approximately
5-10% of the BALB/c myeloma proteins bind a restricted
spectrum of simple haptens, including dinitrophenol, phos-
phorylcholine, and various simple carbohydrate moieties (5).
This frequency is much greater than would be expected from
the frequency of lymphocytes binding the same haptens in
normal individuals (6). Accordingly, the BALB/c myeloma
proteins appeartto represent a restricted sample of the potential
functional repertoire of the BALB/c mouse. Second, nearly all
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of the BALB/c myeloma heavy chains screened thus far have
unblocked NH2-terminal groups, whereas only about 20% of
the serum heavy chains are unblocked (7). The presence of
blocked and unblocked NH2-terminal groups is indicative of
different V subgroups (8). Thus, the BALB/c myeloma proteins
and serum immunoglobulins reflect different distributions of
V subgroups and, presumably, different antibody specificities.
Finally, when the residue alternatives at certain positions of
myeloma sequences are compared to their counterparts from
the normal serum pool, it is clear that some residues in the
myeloma pool are not found in the normal pool (9). Conversely,
residue alternatives found in the normal pool are missing from
the myeloma pool. These differences again suggest that the
normal and myeloma pools of sequences express somewhat
different subsets of the antibody repertoire.
Selection also appears to operate at the level of myeloma
constant regions. Indeed, two-thirds of BALB/c myeloma im-
munoglobulins are of the IgA class whereas less than 10% of the
circulating immunoglobulins are of the IgA class (10). Thus,
there is evidence from both V and constant regions that the
BALB/c myeloma proteins do not represent a random selection
of normal serum antibody molecules.
The observation that myeloma tumors can be induced in a
second inbred strain of mice, NZB, permits us to compare two
populations of myeloma immunoglobulins induced within a
single species, the mouse (11). In this paper we report on the
antigen-binding properties and immunoglobulin class distri-
bution of NZB myeloma immunoglobulins as well as the
NH2-terminal sequences from 27 K chains. These studies suggest
that the myeloma proteins from the BALB/c and NZB mice
constitute two populations of immunoglobulins with distinct
functional and structural properties.
MATERIALS AND METHODS
Myeloma Tumors. The plasmacytomas used for these studies
were induced in NZB/NIH mice.
Immunoglobulin Class Identification and Antigen-Bind-
ing Assays. The serological techniques for immunoglobulin
class identification and the antigen-binding assays will be de-
scribed elsewhere.
Immunoglobulin Production. Plasmacytomas were pas-
saged subcutaneously in (NZB X BALB/c)Fj hybrid mice.
These F1 mice were produced at the Institute for Cancer Re-
search (ICR) from matings of NZB/NIH and BALB/c ICR
mice. The tumors secreting myeloma proteins were passaged
intraperitoneally to 30-50 (NZB X BALB/c)F1 mice primed
Abbreviations: Pi/NaCI, phosphate-buffered saline; V region, variable
region.
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1 week prior to passage with 0.5 ml of pristane (2,6,10,14-te-
tramethylpentadecane; Aldrich). The ascites fluid from these
mice was collected and pooled.
Immunoglobulin Purification. The ascites fluids obtained
from tumor-bearing mice were clarified by centrifugation at
15,000 X g for 10-18 min. An equal volume of phosphate-
buffered saline (Pi/NaCl) with azide and EDTA (0.15 M
NaCI/0.01 M P04/1 mM Na azide/1 mM EDTA, pH 7.4) was
added and diluted 1:1 with a neutral solution of saturated am-
monium sulfate. Volumes containing about 200 mg of protein
were applied to Sephadex G-200 columns equilibrated Pi/
NaCl/azide/EDTA.
Reduction/Alkylation. The peak corresponding to the
myeloma protein was concentrated to 20 mg/ml and dialyzed
against 0.15 M Tris*HCI, pH 8/0.15 M NaCl/2 mM EDTA, pH
7.0. Then, 0.01 vol of 1 M dithiotheitol was added and the so-
lution was stirred at 37"C for 1.5 hr. The sample was then
placed in an ice bath and 0.022 vol of 1 M iodoacetamide was
added. The alkylation reaction was terminated by the addition
of dithiothreitol to a molarity equal to that of the iodoacetamide
added. The solution was dialyzed against 8M urea in propionic
acid for 2 hr.
Separation of Heavy and Light Chains. Reduced and al-
kylated proteins were fractionated on Sephadex G-150 columns
equilibrated in urea/propionic acid. Pooled light chains were
dialyzed against water and lyophilized.
Automated Sequence Analysis. The amino acid sequence
analysis of the light chains was carried out on a Beckman 890A
Sequencer using a dimethylbenzylamine program as described
(12-14). Briefly, aliquots of the phenylthiohydantoin derivatives
of the amino acids were identified by gas chromatography and
thin-layer chromatography. The amino acid derivatives were
also hydrolyzed to free amino acids and analyzed on a Durrum
D-500 amino acid analyzer as described (13). A high-pressure
liquid chromatography system (Waters Associates, Inc., Milford,
MA) using a pH 4.27 buffer system (sodium acetate/water/
methanol) was used to identify the amino acid derivatives from
some of the proteins. Generally, each protein was analyzed a
single time. Repetitive yields ranged from 85-92%.
Mathematical Analyses. Fifty published NH2-terminal
sequences of K chains from BALB/c mice were compared with
the 27 NZB K chains presented in this paper. Mathematical
techniques have been developed which allow us to ask several
questions of these two populations of K sequences (15). First,
given one set of proteins (e.g., the BALB/c K chains), what is the
likelihood that a second set of proteins (e.g., the NZB K chains)
were drawn from the same population of sequences? Second,
in quantitative terms, how much diversity exists within each
population of sequences? These mathematical techniques can
be summarized briefly as follows.
To determine whether the BALB/c and NZB sequences
come from the same pool, one calculates a diversity distance
index [D(B,N)] in which D is the diversity distance, B is the
BALB/c sequences, and N is the NZB sequences. The diversity
distance index is a measure of the similarity of the amino acid
distributions in the two sets of sequences. The significance of
the distance index is estimated by creating a statistical model
that uses a randomly chosen second set of 27 BALB/c sequences
drawn from the complete set of BALB/c sequences. Then one
calculates the most likely distance [,u(B,27)] this second set will
have from the original BALB/c set and the standard deviation
[6(3,27)] of the distance index from ;t(B,27) if one repeats the
random selection many times. Thus, to ask if BALB/c and NZB
K chains are drawn from the same pool, one calculates the dis-
tance index D(B,N) and compares this to ,i(B,27) and b(B,27).
If the difference between D(B,N) and ,t(B,27) is greater than
2 X 0(B,27), one can conclude that the BALB/c and NZB are
drawn from different pools.
The diversity within each set of proteins can be determined
by calculating the distance index for each sequence of a pop-
ulation to the population as a whole and averaging all of the
individual distances. This gives a quantitative measure of the
diversity within a population, designated the variation index
of W(B) for the case of the BALB/c sequences.
Relatedness Trees. Amino acid sequence data can be visually
compared by drawing relatedness or genealogical trees that
depict a theoretical ancestry of the sequences based on the as-
sumption of minimizing mutational events. Distances on the
tree are proportional to the number of genetic events (substi-
tutions, deletions, insertions) that are needed to account for
sequence differences. Where the tree branches (nodal points),
a gene duplication is represented with the sequences below the
branch point sharing a common ancestor.
Relatedness trees were prepared by a variation of the method
of Fitch and Margoliash (16). Data from the BALB/c K chain
sequences are taken from Hood et al. (9). Because of the large
number of sequences, the proteins were assigned to one of four
subpopulations according to their relatedness, and a detailed
tree was constructed for each subdivision. The four trees werejoined by making a master tree of selected members of each
separate tree.
RESULTS AND DISCUSSION
Nature and Extent of V Region Diversity Are Similar in
NZB and BALB/c Myeloma X Light Chains. Twenty-seven
V regions from light chains (VL) of NZB immunoglobulins were
analyzed by automatic sequence analysis (Fig. 1). Nineteen of
the VK sequences are distinct from one another, differing by as
many as 13 residues.
By several criteria the diversity of NZB and BALB/c mye-
loma K chains is similar even though they appear to be drawn
from distinct sets of proteins. (i) The distribution of variation
in the first 23 residues is similar (Fig. 1). For example, the pools
of myeloma K chains for both strains show little variation at
positions 5, 6, and 16, whereas positions 9-12, 15, 17, and 18
vary extensively. (ii) The degree of variation as measured by
the variation indices W(B) and W(N) for 23 residues is similar
for the BALB/c and NZB pools of K chains (Table 1). (Mii) The
BALB/c and NZB K chains both exhibit size variation in the first
hypervariable region. For example, the NZB light chains fall
into a minimum of four different size classes with 33, 34, 35,
or 38 residues before the invariant tryptophan that terminates
the first hypervariable region. Thus, the great diversity of the
NZB and BALB/c K chains in the first 23 residues extends
through the first hypervariable region and, accordingly, will
be reflected in the diversity of the corresponding antigen-
binding sites. (iv) As has been found with BALB/c V regions,
there is a correlation between the size of the first K chain hy-
pervariable region and the NH2-terminal sequence (17, 18).
Indeed, light chains that are identical in their first 23 amino
acids invariably have first hypervariable regions of identical
size. For example, one pair of NZB K chains with 38 residues
before the invariant tryptophan have the same NH2-terminal
sequence (i.e., PC3741 and PC2880). The same is true of a
second pair with 35 residues (PC144 and PC2419) and a third
pair with 34 residues (PC3609 and PC3612). This correlation
is true of other sequences in the literature including several sets
of K chains from antigen-binding proteins and the set of closely
related BALB/c K chains including M321, M70, M653, and
T124.
Pool of NZB Myeloma Proteins Appears To Be Distinct
from the Pool of BALB/c Myeloma Proteins by Several
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Criteria. The pools of NZB and BALB/c myeloma proteins
differ from one another by three criteria: immunoglobulin lass
distribution, antigen-binding properties, and amino acid se-
quence. (i) The expression of myeloma immunoglobulin classes
in these two strains is quite distinct in that the distribution of
NZB myeloma population assessed to date (t600 proteins) is
52% in the IgG class and 21% in the IgA class, whereas the dis-
tribution of the BALB/c myeloma population is 22% in the IgG
class and 46% in the IgA class (unpublished data; see ref. 4).
Thus, the myeloma process amplifies different ratios of im-
munoglobulin classes in these two inbred strains even though
the same method of induction is used. (ii) The NZB myeloma
proteins tend to bind different haptens than do-the BALB/c
myeloma proteins (Table 2). For example, it is striking that none
of the NZB myeloma proteins, of >200 screened, bind dini-
trophenol or phosphorylcholine, two of the most common
haptens bound by BALB/c myeloma proteins. Indeed, 12 NZB
myeloma proteins from those screened bind DNA (unpublished
data), whereas few BALB/c proteins bind this antigen (19). (ffi)
The VK regions from the NZB and BALB/c myeloma proteins
appear to form distinct populations of amino acid sequences.
The third supposition is supported by three observations.
(i) The NH2-terminal 23 residues of 17 V sequences of NZB
myeloma K chains have been examined (Fig. 1). Nineteen dif-
ferent VK sequences are found among them and only 1 of these
sequences is identical to any of the 43 different BALB/c V,
sequences available for comparison over this region. Identity
of but a single VK sequence between NZB and BALB/c popu-
lations would be expected if the pool of possible V sequences
in mice is so large that few repetitions would be seen. However,
both the BALB/c and NZB pools of sequences show multiple
repeats of V regions examined over their NH2-terminal 23
residues. For example, within the NZB pool of VK regions, two
identical pairs of sequences appear (e.g., PC2367 and PC2316)
Table 1. Statistical comparison of NZB and BALB/c light chains
Diversity distance D(B,N) = 4.99
Expected distance D(B,27) = 3.69
Standard deviation j(B,27) = 0.60
Probability (assuming normality) <0.015
Internal diversity, BALB/c W(B) = 18.6 ± 2.8
Internal diversity, NZB W(N) = 21.5 k 1.2
B = 50 BALB/c sequences; N = 27 NZB sequences.
and three probably identical triplets appear (e.g., PC144,
PC2419, and PC2454). In addition, the BALB/c sequences
demonstrate at least 12 pairs of identical VK regions (9). Thus,
if the NZB and BALB/c myelomas were drawn from the same
pool, one would expect more V sequences to be shared by the
NZB and BALB/c myeloma K chains.
(ii) A relatedness analysis of the NZB and BALB/c K se-
quences also suggests that they constitute, at least in part, dis-
tinct populations. Fig.- 2 is a relatedness tree which graphically
displays the sequence relationships of the NZB and BALB/c
myeloma K chains in their first 23 residues. Individual immu-
noglobulin chains are represented by number designations at
the terminal twigs of the tree. The NZB V regions are boxed to
distinguish them from the BALB/c VK counterparts. Many NZB
sequences are three or more base changes from their nearest
BALB/c counterpart. For example, the PC2316, PC2367, and
PC2200 cluster in the upper right and the PC144, PC2419, and
PC2454 set in the lower left constitute groups of related NZB
sequences that have no BALB/c counterparts. Conversely, sets
of related K chains of the BALB/c set such as the TEPC15 and
HOPC8 set have no NZB counterpart.
(iii) We have found a diversity distance index D(B,N) of 4.99
as a measure of the difference between the distributions of
amino acids in the first 23 residues of the BALB/c and NZB
Position
Light
Chain
PC2408
PC2367
PC2316
PC3612
PC3609
PC3249
PC2200
PC118
PC39
PC920
PC938
PC144
PC2419
PC2454
PC613
PC674
PC2880
PC3741
PC1229
PC2155
PC2787
PC2205
PC2567
PC2954
PC3858
PC3936
PC2279
PC373
PC2426
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D V V V TQ T P L SL P V S F G D Q V S IS C
D I V M TQ S Q K FM S T S V G D R V S IT C
D I V L T Q D E I S N P V T S G E R V X I S C
D I Q M T Q S (S) S S F (S) V S L G B R V T I T C
E I V L TQ S P A LM A A X P G Z K V T IT C
S E
S E
DI Q M T Q SP S XL S A S L G K G V T IT C
D I Q M T QSP A SL S V S V G E T V T IT C
D I V L T QSP A SL A V S L G Q R A T IT C
z
E I V L TQ SP A IT A A S L G Z K V T IT C
D I Q M TQ SP S SL A A S L G Z R I S LT C
D V V M TQ TP L S L P V S L G D Q A S IS C
D I Q M T
D I L L T
D I Q M T
D V Q I T
Blocked
Blocked
Q S M A S L S A S V G Z T V
Q S P A T L S V S P G E R V
Q S P S N L S A S L G E R V
Q S P S Y L A A S P G E (T) I
T I T
S F S
S L T
T I N
C
C
C
C
Heavy Chain
Class
IgG2b
IgG2a
IgA
IgG2b
IgG2b
IgGl
IgG2a
IgA
IgG2a
IgA
IgG2a
IgG2a
IgA
IgG2b
IgM
IgG2a
IgG2b
IgM
IgG2b
Ig3
IgA
IgA
IgA
IgG2b
IgG2b
FIG. 1. NH2-terminal amino acid sequences of NZB K chains (one-letter amino acid code). X denotes an unknown residue. Brackets indicate
an uncertainty of sequence assignment. "Blocked" denotes that the a amino group is covalently blocked and not free for the Edman reaction.
Blanks indicate unassigned immunoglobulin class.
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Table 2. Antigen binding spectrum of NZB and BALB/c
myelomas
NZB BALB/c
DNA ++ -
Dinitrophenol - ++
Phosphorylcholine - ++
a-1,3-Dextran - +
a-1,6-Galactan - +
a-1,6-Dextran + +
+, 1-10 tumors of that specificity have been found; ++, >10 tumors
found.
light chains (Table 1). Randomly chosen sets of sequences taken
from the BALB/c population would give a diversity distance
index [D(B,27)] of only 3.69 with a SD of 0.60. Thus, the NZB
sequences deviate from their BALB/c counterparts by more
than two SD and, accordingly, the probability these two pop-
ulations of proteins were chosen from the same pool is small
(<0.015).
Why Does the Myeloma Process in BALB/c and NZB
Mice Appear to Transform Distinct Populations of Lym-
phocytes? The complete or nearly complete sequences of 19
NZB VK regions of one frequently expressed subgroup (VK21)
have been determined (unpublished data). Several of these VK
regions are identical to BALB/c VK regions. Accordingly, the
NZB and BALB/c mice share some identical VK region. Thus,
two models may account for the apparent transformation of
distinct populations of lymphocytes during the induction of
myeloma tumors in NZB and BALB/c mice. The BALB/c and
NZB mice may have certain distinct V genes or they may have
genetic differences, outside the V structural genes, that either
produce different antigenic exposures (e.g., susceptibility to
viral infections) or operate as distinct control elements to
modulate V gene expression. Obviously, both of these possi-
bilities could be true.
Certain distinct V genes could have been fixed in these strains
from polymorphisms that preexisted in their ancestors. If so,
different V regions could be expressed in these strains. Thus,
some of the sequences found in one strain but not in the other
(Fig. 2) may constitute structural gene polymorphisms. This
hypothesis does not explain the distinct immunoglobulin class
distribution in the myeloma proteins of these two strains, nor
does it account for the observation that the myeloma proteins
in the two strains bind distinct sets of antigens (Table 2) because
a response to any of these haptens can be obtained in immu-
nized animals from either strain.
An alternative and perhaps more likely explanation is that
genetic differences outside the V genes lead to the expression
of distinct populations of V genes in the lymphocytes of these
strains. For example, the physiological differences in these two
strains may lead to distinct internal antigenic environments,
or distinct regulatory elements in the two strains may lead to
the clonal expansion of (or induction of tolerance in) different
sets of lymphocytes in the two strains. Hence, the myeloma
process would transform distinct populations of lymphocytes
in these two strains. This supposition is consistent with the ob-
servation that NZB but not BALB/c mice develop autoimmune
disease with the concomitant expansion of clones of lympho-
cytes to self antigens (20) and that these antiself immunoglob-
ulins are seen in the NZB but not the myeloma proteins. For
example, 12 different NZB myeloma proteins bind DNA
whereas few, if any, of their BALB/c counterparts do (Table
2). This model proposes that the same structural genes for both
sets of V sequences exist in both strains but that other genetic
differences create distinct internal conditions that lead to the
expression of different subsets of V genes. A possible way to
differentiate between the models would be through nucleic acid
1773
,TEPC 157
312
MOPC '
'149
MOPC 41
FIG. 2. Relatedness tree of mouse light chains. Boxes enclose NZB light chains. Examples of BALB/c light chain sequences with multiple
members are not indicated. Lengths of lines connecting proteins and nodes indicate the minimal number of base substitutions. [A preliminary
form of this relatedness tree was published in ref. 4 and has been refined with additional data and computer searches for a tree with minimal
branch lengths (see ref. 16).]
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chemistry, by determining whether identical structural genes
for individual K chains exist in both strains. The final answer
may be that both models are partially correct.
Because Myeloma Proteins Appear to Represent Only a
Subset of the Total Lymphocyte Repertoire That the Mouse
Can Express, V Gene Counting from Myeloma Data Provide
Only Minimal Estimates of Antibody Gene Diversity. There
are several reasons for believing that the myeloma populations
in BALB/c and NZB mice represent only a subset of the total
immunoglobulin diversity these mice are capable of producing.
(i) The antigen-binding spectra are quite distinct (Table 2) even
though both strains can, by immunization, produce specificities
not seen in the myeloma population. (ii) The normal pool of K
chains has residue alternatives not seen in the myeloma pool
and vice versa (9). (iii) The VH subgroup distributions in the
myeloma population and in normal immunoglobulins are quite
distinct. Accordingly, the myeloma process provides a window
through which we can glimpse the antibody repertoire, but the
window probably views just a fraction of the total diversity.
Because it is impossible to say how small this fraction is, it is
difficult to estimate what fraction of the antibody repertoire
is expressed by the myeloma process in each of the inbred
strains. Estimates of the number of V subgroups in the antibody
families, based on the sequence analysis of myeloma proteins,
are therefore minimal estimates and could be far too low. Thus,
the number of V genes in many antibody families may be
substantially higher than previously estimated.
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